Magnetic resonance-only prostate simulation achieved 96.80% local gamma agreement using synthetic computed tomography for dose calculation.
Surface-guided radiotherapy kept mean setup shifts near zero during frog-leg vulvar volumetric modulated arc therapy.
An international Delphi panel approved a three-step acute radiation dermatitis tool integrating patient-reported symptoms and clinician assessment.
Dose-dependent linear energy transfer constraints aligned with published proton toxicity data better than fixed threshold approaches.
Partial breast irradiation projected lower lifetime secondary lung cancer risk than whole breast irradiation in Korean early-stage breast cancer cohorts.
Photon-counting computed tomography generated effective atomic number and physical density images directly from virtual monoenergetic images.
Rectal air or air-filled balloons did not cause clinically relevant dose increases when posterior tissue shifts stayed within 5 millimetres.
Feature-wise scanning Mamba improved liver radiotherapy segmentation accuracy while reducing model size and inference time.
The SunSILICON detector directly measured electron beam depth doses, profiles, and output factors with close agreement to reference detectors.
A conditional generative adversarial network predicted clinically acceptable esophageal radiotherapy dose distributions, but systematic target underdosage limited clinical use.
Cherenkov light imaging tracked gold implant motion in water with submillimetre accuracy during static and volumetric modulated arc therapy delivery.
Upright computed tomography showed stable computed tomography numbers and greater than 99% proton dose gamma agreement versus conventional computed tomography.
All eight radiotherapy planning computed tomography scanners showed measurable geometric distortion, with maximum values up to 1.88 millimetres.
An automated report-based chart checker detected residual errors in 37.1% of manually reviewed external beam radiotherapy plans.
Simultaneous integrated boost radiotherapy was associated with 96% two-year disease-free survival versus 70% with sequential boost in anal cancer.